Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies-Reference-Cited by-同舟云学术

Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies

Published:2016-11-26 Issue:1 Volume:101 Page:89-98
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Roberts AW¹²³⁴,Huang DCS²³

Affiliation:

1. Integrated Department of Clinical Hematology; The Royal Melbourne Hospital and Peter MacCallum Cancer Centre; Parkville Australia

2. Cancer and Haematology Division; Walter and Eliza Hall Institute of Medical Research; Parkville Australia

3. Faculty of Medicine, Dentistry, and Health Sciences; The University of Melbourne; Parkville Australia

4. Victorian Comprehensive Cancer Centre; Parkville Australia

Funder

the National Health and Medical Research Council of Australia

the Cancer Council of Victoria

the Leukemia and Lymphoma Society

the Victorian Cancer Agency

the Australian Cancer Research Foundation

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference70 articles.

1. Involvement of the bcl-2 gene in human follicular lymphoma;Tsujimoto;Science,1985

2. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells;Vaux;Nature,1988

3. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation;McDonnell;Cell,1989

4. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2;Strasser;Nature,1990

5. The Bcl2 family: regulators of the cellular life-or-death switch;Cory;Nat. Rev. Cancer,2002

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

2. Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies?;Blood Advances;2024-07-09

3. Targeting apoptosis in clear cell renal cell carcinoma;Biomedicine & Pharmacotherapy;2024-06

4. Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells;Frontiers in Immunology;2024-05-15

5. Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2;Journal of Medicinal Chemistry;2024-05-02